The loss of functional Survival Motor Neuron (SMN) protein due to mutations or deletion in the SMN1 gene causes autosomal recessive neurodegenerative spinal muscle atrophy (SMA).
proteins) is a known ARE binding protein (AREBP) which in some cases, antagonizes the degradation of these mRNA by stabilizing them (12) (13) (14) (15) . Activation of the p38 pathway has been shown to lead to a cytoplasmic accumulation of HuR protein with its increased binding to target mRNAs, resulting in there stabilization (6, 16) . Our group has previously shown that the p38 MAPK activation induces SMN expression in this fashion; triggering HuR mediated stabilization of SMN mRNA and increases the pool of transcripts available for translation thus increasing functional SMN protein levels (6) .
In our previous work, the known p38 MAPK activator anisomycin was used; however this drug cannot cross the blood brain barrier (BBB) thus limiting its ability to act in vivo on the central nervous system in particular the motor neurons, where the lack of SMN contributes to SMA pathophysiology. A search of the literature identified the FDA approved selective COX-2 (cyclo-oxygenase 2) inhibitor non steroidal anti-inflammatory drug celecoxib as an alternative to anisomycin which besides showing p38 activation in some system, also crosses the BBB making it a good candidate for further exploration as an SMA therapeutic (17) (18) (19) .
We show here a celecoxib conferred increase in SMN protein in both neuronal cells and wild type (WT) mice. We present in vitro evidence that celecoxib activates the p38 pathway leading to increase SMN mRNA and a subsequent increase in SMN protein. Importantly, we show that treatment with celecoxib increases SMN levels, improves motor function and survival in a severe SMA mouse model. Our results confirm earlier work proposing p38 MAPK pathway activators as potential therapeutic compounds for the treatment of SMA, identifying celecoxib as one such promising agent. 
Celecoxib treatment upregulates SMN protein in vitro
To investigate a potential role celecoxib in the regulation of the SMN gene expression in vitro; NT2, MN-1 cells along with SMA I patient fibroblasts were treated with celecoxib (5nM) for 24 h and subsequently harvested for Western blot analysis. SMN protein levels were found to be increased in all cell lines upon treatment with celecoxib ( Fig. 1 a-c) . These results show that low dose (nM range) of celecoxib increases SMN protein levels in both human and mouse neuronal cell lines as well as in SMA patient fibroblasts.
Celecoxib activates the p38 MAPK and increases SMN protein levels in a time dependent manner in vitro
Since the p38 pathway has been implicated in the regulation of the SMN gene, and given that celecoxib has been shown to be an activator of this pathway, we wished to confirm that at concentrations we have shown induce SMN, celecoxib also activates the p38 MAPK pathway. NT2 cells were thus treated with celecoxib at 5 nM and then harvested for Western blot analysis at the indicated time intervals revealing a time-dependent increase in the ratio of phosphorylated-p38/ total p38 protein (up to 8 hr after celecoxib treatment). This confirms that celecoxib activates the p38 MAPK pathway in NT2 cells (Fig 2 a-b) . We also found that activation of the p38 MAPK pathway by celecoxib treatment was followed by a time dependent increase in SMN protein level in NT2 cells (Fig 2 a & c) .
Activation of p38 pathway and HuR protein are required for celecoxib-conferred SMN protein increase
To investigate a potential role for p38 in SMN gene regulation by celecoxib, NT2 cells were pre-treated with the p38 inhibiting agent SB-239063 for 2 h followed by treatment with celecoxib for 24 h. Western blot analysis revealed that p38 inhibition effectively blocked the celecoxib-mediated increase in SMN protein (Fig 3 a & b) . We have shown previously that upon p38 pathway activation, HuR protein binds to 3'UTR of SMN transcript which leads to increase in SMN levels. To further elaborate the role of HuR protein in celecoxib-induced increase in SMN protein, NT2 cells were transfected with HuR-specific siRNA or control siRNA for 48 h, and then treated with celecoxib for 24 h. siRNA-mediated attenuation of HuR expression blocked the celecoxib-mediated increase in SMN protein expression (Fig 3   c & d) . These observations strongly implicate the p38 pathway and HuR protein translocation in the celecoxib-induced in vitro increase of SMN levels.
Celecoxib treatment upregulates SMN protein levels in wild type mice
In order to both confirm that celecoxib-mediated SMN induction extends to the in vivo setting, and to begin to explore celecoxib treatment in animals, CD-1 mice were given daily intraperitoneal (IP) celecoxib injections for 5 days over a range of doses. Brain and spinal cord samples were subsequently isolated for Western blot analysis. Celecoxib treatment (20 μg/kg) increased SMN protein levels in brain (Fig 4 a & b) and spinal cord samples (Fig 4 c 
Celecoxib treatment upregulates SMN protein levels in a SMA mice model
In order to explore the in vivo impact of celecoxib-induced SMN upregulation, SMN∆7 SMA mice (mSmn-/-;hSMN2+/+, hSMNΔ7+/+ (20)) were given 20 μg/kg celecoxib IP injections every day from P1 until P6. Mice were euthanized 24 hours after their last treatment. Brain, spinal cord, muscle and heart samples were then harvested for Western blot analysis. Importantly, celecoxib treatment was observed to increase SMN2-derived full length SMN protein levels significantly in both brain (Fig 5 a & b) and spinal cord samples (Fig 6 A-E) .
Celecoxib treatment improves disease phenotype in SMA mice model
We next examined the impact of celecoxib-induced increase in SMN levels on disease phenotype in SMA∆7 mice. The SMA∆7 mice have severely impaired righting time and muscle weakness detectable by P5. They are also significantly underweight compared to heterozygous and WT littermates with a median survival of 13 days. SMA∆7 mice were given daily celecoxib or vehicle IP injections starting at P1and their weight, motor function and longevity were assessed daily. SMA∆7 mice treated with celecoxib showed a dramatic improvement of motor function (as assessed by righting time), and significant extension of survival (median survival of 18 days) as compared with vehicle-treated SMA∆7 mice (median survival of 13 days, Fig 7 a & b) . However, SMA∆7 mice treated with celecoxib showed no improvement in weight loss as compared with vehicle-treated SMA∆7 mice ( Supplementary Fig 3) .
Discussion:
SMA is a frequently severe neurodegenerative disease which mostly affects children, many of whom die in the first years of life. Currently, there is no effective therapy for SMA in clinical use. Increasing SMN levels through the SMN2 gene can partially rescue the disease phenotype (21) . One strategy for SMA therapy is to increase levels of SMN protein from SMN2 gene through stabilization of the full length SMN transcript which ultimately leads to an increase in SMN mRNA and protein levels (6) . The p38 pathway regulates a number of cell processes including post transcriptional regulation of a certain class of transcripts with an ARE sequence in their 3'UTR (7-11). We have previously documented that anisomycin, a known p38 activator, increases SMN levels through mRNA stabilization in vitro (6) . However a number of issues need to be addressed in order to recapitulate our in vitro results with anisomycin in a SMA mouse model. The transient increase in SMN levels observed with anisomycin treatment, along with its inability to cross BBB limits its use as a therapeutic for SMA, a motor neuron disease. An alternative to anisomycin is p38 activating, FDA approved COX-2 inhibitor drug celecoxib which can cross the BBB thus making it an ideal candidate to test as a therapeutic for the treatment of SMA. In this study we have demonstrated that celecoxib induces SMN expression in vitro in a p38 and HuR protein dependent fashion.
We document here a celecoxib mediated increase in SMN protein levels in human neuronal NT2 cell line and murine motor neuron MN-1 cells as well as in SMA I patient fibroblasts. It was shown in previous studies that low dose celecoxib activates the p38 pathway (17-19) although not higher doses (18, (22) (23) (24) . Here we treated neuronal cells with a low concentration (nanomolar range) of celecoxib observing a rapid increase in phospho p38 levels followed by an increase in SMN protein levels. The p38 pathway regulates the stability of COX-2, TNFα, p21 and SMN transcripts which are known to contain ARE in their 3'UTR region (6, 8, 10, 16) . To confirm the role of p38 activation in celecoxibmediated increase in SMN protein, cells were pre-treated with a p38 inhibitor before celecoxib treatment. This resulted in an attenuation of SMN induction consistent with a role for celecoxib based activation of p38.
We have shown in an earlier report that in vitro p38 activation-conferred SMN induction is through transcript stabilization via binding of ARE BP HuR to the 3'UTR region of SMN transcripts (6) . A second report showed a similar mechanism for the regulation of p21 mRNA by the p38 pathway and HuR protein (16) . To explore whether a similar role exists for HuR protein in the in vitro celecoxib mediated increase of SMN, NT2 cells were pre-treated with HuR siRNA followed by celecoxib treatment. Celecoxib There are a number of factors which we need to take into account when using SMA mice as a disease model, particularly when comparing results between laboratories (e.g.
health of mice at birth, competition within cage between littermates, housing conditions).
Therefore, to account for this variability, we used the ratio of median survival of treated to non treated animals to assess drug response on survival. With celecoxib we have achieved a ratio of 18d/13d or 1.38, a number that compares favourably with the 1.2 (19d/16d) observed with TSA (albeit P1 celecoxib initiation versus P5 TSA initiation) and 1.3 (12.9d/9.9d) seen with SAHA (30, 31) .
In addition to HDAC inhibitors, antisense oligonucleotides (ASOs), have shown promise for the treatment of SMA by preventing alternative splicing of the SMN2 transcript and ultimately resulting in more full length SMN transcript (32, 33) . A major hurdle with these compounds is their failure to cross the BBB. However, a recent study shows a marked improvement in motor function along with increase in survival in SMA mice with systemic delivery of ASO which results into increase in SMN levels largely in peripheral tissues (32);
It is unlikely however that the systemic effect extends to human given the lack of ASO blood brain barrier penetration. The other encouraging treatment of SMA is gene therapy using sc-AAV9-SMN resulting in a marked increase in longevity of SMA mice along with a significant improvement in motor function (34) . Similar results were seen by other groups who used similar gene therapy approaches (35) (36) (37) . While there is a phase II SMA therapy trial currently underway for intra-thecal ASO, there are a number of issues which need to be addressed before wide spread clinical introduction of gene therapy for SMA (clinical safety, species barrier, quantity of virus, overall cost, immune response) (38, 39) .
Off-target drug effects, either harmful or useful, are commonly observed occurrences. In the current study, celecoxib is used as an alternative to the p38 activating compound anisomycin. Celecoxib was the first in class of selective COX-2 inhibitors to be FDA approved for the treatment of rheumatoid arthritis and osteoarthritis. Although celecoxib causes a lower incidence of gastrointestinal ulceration and other complications than do other non-steroidal anti-inflammatory drugs (40, 41) , the effects are nonetheless real.
A recent study demonstrated possible damage of hepatic and renal tissue when rats were treated with 10 and 50 mg/kg celecoxib doses (42) . However, the doses of celecoxib (20 µg/kg) which we have used for treatment in this study are two orders of magnitude lower than doses currently used for osteoarthritis (1-2 mgs/kg) in humans, and much lower than levels shown by toxicology reports to be harmful (40) making it likely that this would be a safe intervention for the vulnerable demographic comprised by infants and children diagnosed with SMA.
Our results demonstrate clear amelioration of the SMA disease phenotype in mouse model using BBB penetrant, FDA approved celecoxib raising the prospect of its use in clinical trial studies. As many recent studies have shown that early timing of SMN gene therapy is critical for maximum benefit in SMA mouse model, diagnosing newborn presymptomatic SMA infants and their early treatment will be critical. It may even be beneficial for SMA type II and III patients as a recent study showed that increasing SMN levels even post-symptomatically ameliorates SMA disease phenotype (43) . It may be of value to combine the effect of celecoxib with SMN2 transcriptional activator prolactin (25) and/or neuroprotective compounds such as Y-27632 and fasudil (Rho kinase inhibitors) (44, 45) .
Presently there is no effective treatment for SMA. This study provides evidence of low dose celecoxib activation of p38 resulting in significant neuronal SMN protein induction and thus a low cost, clinically practical potential SMA therapy that could be trialed in the immediate future. by the Jackson Laboratory. The animals were maintained in an air-conditioned ventilated animal facility. Survival, righting time and weight were monitored daily as described by Aviva et al (30) .
Celecoxib administration
Celecoxib was diluted in DMSO and administered through IP injection using a 30-gauge needle. Control animals received equal volumes of vehicle alone. SMA∆7 mice were genotyped at P0 and celecoxib treatment was started from P1. Animals were sacrificed within twenty four hours of final celecoxib dose.
Reagents
Celecoxib was purchased from Toronto Research Chemicals. p38 inhibitor SB239063 was purchased from Sigma. Non-silencing siRNA control and HuR siRNA were purchased from Qiagen and Dharmacon respectively. The antibodies used in this study were SMN/Smn (BD Transduction Laboratories), Actin (Abcam), Tubulin (Abcam), Phospho-p38 (Cell signalling) and Total p38 (Cell signalling).
Primer sequences

For genotyping
Genotyping was performed as previously described by Aviva et al (30) 
Western Blot Analysis
Cells were washed 2 times with 1 ml PBS (1X) and lysed in 75μl RIPA buffer containing 10 mg/ml each of aprotinin, PMSF and leupeptin (all from Sigma), 5 mM β-Glycerolphosphate, 50 mM NaF and 0.2 μM sodium orthovanadate for 30 min at 4°C, followed by centrifugation at 13 000 x g for 15 min; supernatants were then collected and kept frozen at -20°C. Tissue samples were homogenized in 1 ml RIPA (10 mg/ml each of aprotinin, PMSF and leupeptin) and then sonicated for 15 seconds. Total protein concentrations were determined by Bradford protein assay using a Bio-Rad protein assay kit. For Western blot analysis, protein samples were separated by 10% SDS-PAGE. Proteins were subsequently transferred onto nitrocellulose membrane and incubated in blocking solution (PBS, 5% non-fat milk, 0.2% Tween-20) for 1 h at room temperature followed by overnight incubation with primary antibody at 4°C at the dilution prescribed by the manufacturer. Membranes were washed with PBS-T (PBS, and 0.2% Tween-20) 3 times followed by incubation with secondary antibody (anti-mouse or rabbit, Cell signalling) for 1 h at room temperature. Antibody complexes were visualized by autoradiography using the ECL Plus and ECL Western blotting detection systems (GE Healthcare). Quantification was performed by scanning the autoradiographs and signal intensities were determined by densitometric analysis using the Odyssey v1.1 program.
Immunofluorescence staining and confocal microscopy:
Spinal cords where briefly rinsed in PBS, fixed for 6 hours in 4% paraformaldehyde in PBS and then transferred for cryopreservation into 30% sucrose/PBS prior to the making of the Confocal microscope settings remained constant for each of the channels imaged. Channels were acquired in a sequential mode, the lasers output was set at 5% and the confocal aperture was set at 176 µm. 
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